Results 101 to 110 of about 93,969 (303)
Allergy, EarlyView.HDM‐pSLIT induced IgG, IgG1, and IgG4 specific to major HDM allergens in sensitized non‐allergic preschool children without increasing HDM‐sIgE. It blunted the development of new sensitizations and reduced HDM reactivity in skin and basophils. HDM‐pSLIT treated children displayed a blocking effect on HDM‐induced basophil activation.
Varsha Dwivedi +12 more
wiley +1 more source
Allergy, EarlyView.Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian +18 more
wiley +1 more source
Use of Topical Steroids in Conjunctivitis: A Review of the Evidence.
Cornea, 2019 PURPOSE Conjunctivitis, or inflammation of the conjunctiva, is a common condition that can be caused by infectious (eg, bacterial or viral infections) and noninfectious (eg, allergy) etiologies.
E. Holland, M. Fingeret, F. Mah
semanticscholar +1 more source
Allergy, EarlyView.ABSTRACT Mucosal surfaces are sites of highly dynamic interactions among epithelial and immune cells, environmental exposures, particularly dietary inputs, and the diverse microbial communities and their metabolites. These elements continually influence each other to maintain homeostasis and ensure appropriate immune discrimination between pathogens ...
Clara Delaroque +5 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To report treatment patterns, time‐to‐resolution (TTR) and aetiologies of bacterial keratitis (BK) infections treated in a specialized hospital‐based cornea clinic in Sweden. Methods Retrospective study based on electronic health records screened during the period 2010–2019. The study included only culture‐confirmed cases of BK.
Jenny Roth +5 more
wiley +1 more source
Three years of ocular proton therapy in the Netherlands, clinical results
Acta Ophthalmologica, EarlyView.Abstract Purpose Uveal melanoma (UM) is a rare cancer with rising number of diagnosis (143 diagnoses in 1990 to 226 in 2023) in the Netherlands. Most patients are treated locally with Ruthenium‐106 brachytherapy (±102/year). Patients were referred for proton therapy (PT) to Switzerland in the past, but PT is available in the Netherlands from January ...
C. Rasch +14 more
wiley +1 more source
Acta Paediatrica, EarlyView.ABSTRACT Aim To evaluate the association between reported symptoms upon exposure to airborne allergens and sensitization to the corresponding allergen. Method In a population‐based cohort, 1647 children aged 12 years were interviewed about symptoms from eyes, nose and lower airways upon exposure to birch, timothy, cat, dog, and horse, and were ...
E. Rönmark +5 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend +16 more
wiley +1 more source
IMMUNOPATHOLOGY OF ALLERGIC CONJUNCTIVITIS
European Medical Journal, 2020 Allergic conjunctivitis is predominantly an immunoglobulin E-mediated hypersensitivity reaction to environmental allergens. Allergic diseases affect >30% of the world’s population, of which 40% report associated ocular manifestations.
DeGaulle I. Chigbu, Bhawanjot K. Minhas
doaj
British Journal of Haematology, EarlyView.Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova +15 more
wiley +1 more source